CNTN Filings — Canton Strategic Holdings, Inc. - FilingSpy
CNTN
Canton Strategic Holdings, Inc.
A New Jersey company running a "digital asset treasury" around the Canton Network, a privacy-focused blockchain for institutional finance, where it operates as a "Super Validator" managing Canton Coin. It began in 2017 as Tharimmune, a biotech working on a treatment for the severe itching of liver disease, before pivoting and rebranding in early 2026. The name nods to Switzerland's cantonal system, whose semi-independent regions work together like one country — much like the network's own design.
A $23.7M unrealized loss on digital assets drove a $19.3M net loss as the company completed its pivot from biotech to a digital asset treasury.
The company's strategic shift is complete, and its results now reflect a digital asset treasury, not a biotech pipeline. of $1.5 million was recorded for the first time, but a $23.7 million on Canton Coin holdings pushed the net loss to $19.3 million. The company is funded through early 2027, but its performance is now tied to the price of a single digital asset.
Key takeaways
A $23.7 million on digital asset holdings was the primary driver of the $19.3 million net loss, as the reference price of Canton Coin fell below the company's .
The company reported its first , totaling $1.5 million, from network validation rewards and Locking-as-a-Service agreements, marking the operational start of its new digital asset strategy.
General and administrative expenses rose 107% to $2.7 million, driven by higher compensation, insurance, and digital asset custody costs tied to the new business.
Section summaries
Management's Discussion and Analysis
Revenue began from Canton Network validation and CC locking services, but a $23.7M unrealized CC loss drove a $24.6M net loss in Q2 2026.
⌄
Total was $1.5M in Q2 2026, consisting of $0.2M in network validation rewards from a 0.5 weight SV unlock and $1.3M in other revenue primarily from Locking-as-a-Service (LAAS) agreements.
General and administrative expenses rose 107% to $2.7M, driven by higher compensation, insurance, and digital asset custody costs, partially offset by lower .
Legacy research and development expenses fell to zero, as the company classified its former biotechnology operations as discontinued, completing the strategic pivot.
Cash and equivalents fell 10.3% sequentially to $37.2 million, while total assets declined 3.4% to $564.6 million, reflecting the impact of the on the balance sheet.
What changed
The going-concern warning that had been present in every prior filing was removed in the previous quarter and remains absent; management stated liquidity is sufficient to fund operations through at least March 2027.
The fair value of digital asset holdings, flagged as a key watch item, produced a $23.7 million this quarter, following a $15.0 million loss in Q1 2026 and a $22.0 million loss in FY2025.
The use of financing proceeds for digital asset purchases continued, with the company completing the sale of its Gravitas subsidiary in July 2026 for a $3.5 million promissory note, further divesting legacy assets.
The impact of equity offerings flagged in prior periods materialized as fell this quarter, but the cumulative effect of prior awards remains a factor in the expanded share base.
What to watch
The fair value of the company's Canton Coin holdings and any further unrealized gains or losses, given the $23.7 million loss this quarter and the cumulative $60.7 million in unrealized losses over the past three quarters.
The sustainability and growth of the new streams from network validation and Locking-as-a-Service, which generated $1.5 million this quarter and will need to scale to offset operating costs.
Any disclosure on the impact of the January 2026 registered direct offering and the awards tied to the digital asset strategy on existing shareholders.
A $23.7M on digital asset holdings was recorded for Q2 2026, as the reference price of CC fell below the of the Company's holdings.
The Company's strategic shift to a digital asset treasury is complete, with legacy biotechnology R&D expenses falling to zero as those operations are classified as discontinued.
Liquidity was strengthened by a registered direct offering in January 2026, and the Company completed the sale of Gravitas in July 2026 for a $3.5M and potential milestone payments.
Quantitative and Qualitative Disclosures About Market Risk
The Company is not required to provide the information required by this Item as it is a “smaller reporting company,” as defined in Rule 12b-2 of the Exchange Act. ITEM
⌄
The
Company is not required to provide the information required by this Item as it is a “smaller reporting company,” as defined
in Rule 12b-2 of the Exchange Act.
ITEM